Editas Medicine (EDIT) Stock Forecast & Price Target

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

$5.55

-0.06 (-1.07%)

(As of 04/18/2024 ET)

Editas Medicine Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$15.00
170.27% Upside

High Forecast	$20.00
Average Forecast	$15.00
Low Forecast	$9.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$15.00	$15.00	$14.38	$15.33
Predicted Upside	170.27% Upside	60.58% Upside	67.91% Upside	46.92% Upside

Get Editas Medicine Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

EDIT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Editas Medicine Stock vs. The Competition

Type	Editas Medicine	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	170.27% Upside	927.96% Upside	12.32% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
2/29/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$11.00 ➝ $16.00	+50.80%
2/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $11.00	-0.63%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$8.00 ➝ $9.00	+3.09%
12/12/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$15.00 ➝ $20.00	+102.43%
10/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
9/28/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$9.00 ➝ $17.00	+145.66%
8/3/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$12.00	+31.29%
8/2/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$22.00 ➝ $19.00	+107.88%
6/12/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$17.00	+80.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:10 AM ET.

EDIT Price Target - Frequently Asked Questions

What is Editas Medicine's consensus rating and price target?: According to the issued ratings of 9 analysts in the last year, the consensus rating for Editas Medicine stock is Moderate Buy based on the current 4 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $15.00 with a high price target of $20.00 and a low price target of $9.00. Learn more on EDIT's analyst rating history.
Do Wall Street analysts like Editas Medicine more than its competitors?: Analysts like Editas Medicine less than other Medical companies. The consensus rating score for Editas Medicine is 2.56 while the average consensus rating score for medical companies is 2.68. Learn more on how EDIT compares to other companies.
Does Editas Medicine's stock price have much upside?: According to analysts, Editas Medicine's stock has a predicted upside of 60.58% based on their 12-month stock forecasts.

What analysts cover Editas Medicine?: Editas Medicine has been rated by Barclays, Citigroup, and JPMorgan Chase & Co. in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:EDIT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Editas Medicine (EDIT) Stock Forecast & Price Target

Editas Medicine Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

EDIT Analyst Ratings By Month

EDIT Price Targets by Month

Editas Medicine Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

EDIT Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info